Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Discrepancies in central review re-testing of patients with ER-positive and HER2-negative breast cancer in the OPTIMA prelim randomised clinical trial.

Pinder SE, Campbell AF, Bartlett JM, Marshall A, Allen D, Falzon M, Dunn JA, Makris A, Hughes-Davies L, Stein RC.

Br J Cancer. 2017 Mar 28;116(7):859-863. doi: 10.1038/bjc.2017.28. Epub 2017 Feb 21.

PMID:
28222072
2.

Prognostic contribution of mammographic breast density and HER2 overexpression to the Nottingham Prognostic Index in patients with invasive breast cancer.

Masarwah A, Auvinen P, Sudah M, Dabravolskaite V, Arponen O, Sutela A, Oikari S, Kosma VM, Vanninen R.

BMC Cancer. 2016 Nov 2;16(1):833.

3.

HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists.

Fusco N, Bosari S.

World J Gastroenterol. 2016 Sep 21;22(35):7926-37. doi: 10.3748/wjg.v22.i35.7926. Review.

4.

HER2 expression in gastric and oesophageal cancer: a meta-analytic review.

Nagaraja V, Eslick GD.

J Gastrointest Oncol. 2015 Apr;6(2):143-54. doi: 10.3978/j.issn.2078-6891.2014.107.

5.

Guidelines for cytogenetic investigations in tumours.

Hastings RJ, Bown N, Tibiletti MG, Debiec-Rychter M, Vanni R, Espinet B, van Roy N, Roberts P, van den Berg-de-Ruiter E, Bernheim A, Schoumans J, Chatters S, Zemanova Z, Stevens-Kroef M, Simons A, Heim S, Salido M, Ylstra B, Betts DR; Tumour Best Practice meeting; Eurogentest.

Eur J Hum Genet. 2016 Jan;24(1):6-13. doi: 10.1038/ejhg.2015.35. Epub 2015 Mar 25. No abstract available.

6.

Updated UK Recommendations for HER2 assessment in breast cancer.

Rakha EA, Pinder SE, Bartlett JM, Ibrahim M, Starczynski J, Carder PJ, Provenzano E, Hanby A, Hales S, Lee AH, Ellis IO; National Coordinating Committee for Breast Pathology.

J Clin Pathol. 2015 Feb;68(2):93-9. doi: 10.1136/jclinpath-2014-202571. Epub 2014 Dec 8.

7.

Time dependence of biomarkers: non-proportional effects of immunohistochemical panels predicting relapse risk in early breast cancer.

Stephen J, Murray G, Cameron DA, Thomas J, Kunkler IH, Jack W, Kerr GR, Piper T, Brookes CL, Rea DW, van de Velde CJ, Hasenburg A, Markopoulos C, Dirix L, Seynaeve C, Bartlett JM.

Br J Cancer. 2014 Dec 9;111(12):2242-7. doi: 10.1038/bjc.2014.530. Epub 2014 Oct 14.

8.

Antibody validation of immunohistochemistry for biomarker discovery: recommendations of a consortium of academic and pharmaceutical based histopathology researchers.

Howat WJ, Lewis A, Jones P, Kampf C, Pontén F, van der Loos CM, Gray N, Womack C, Warford A.

Methods. 2014 Nov;70(1):34-8. doi: 10.1016/j.ymeth.2014.01.018. Epub 2014 Feb 11.

9.

Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study.

Purdie CA, Quinlan P, Jordan LB, Ashfield A, Ogston S, Dewar JA, Thompson AM.

Br J Cancer. 2014 Feb 4;110(3):565-72. doi: 10.1038/bjc.2013.756. Epub 2013 Dec 3.

10.

Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients.

Engstrøm MJ, Opdahl S, Hagen AI, Romundstad PR, Akslen LA, Haugen OA, Vatten LJ, Bofin AM.

Breast Cancer Res Treat. 2013 Aug;140(3):463-73. doi: 10.1007/s10549-013-2647-2. Epub 2013 Jul 31.

11.

The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: a proof-of-concept study.

Stebbing J, Payne R, Reise J, Frampton AE, Avery M, Woodley L, Di Leo A, Pestrin M, Krell J, Coombes RC.

PLoS One. 2013 May 7;8(5):e62543. doi: 10.1371/journal.pone.0062543. Print 2013.

12.

Cytoplasmic Overexpression of HER2: a Key Factor in Colorectal Cancer.

Blok EJ, Kuppen PJ, van Leeuwen JE, Sier CF.

Clin Med Insights Oncol. 2013;7:41-51. doi: 10.4137/CMO.S10811. Epub 2013 Feb 21.

13.

Development of a single-cell array for large-scale DNA fluorescence in situ hybridization.

Liu Y, Kirkland B, Shirley J, Wang Z, Zhang P, Stembridge J, Wong W, Takebayashi S, Gilbert DM, Lenhert S, Guan J.

Lab Chip. 2013 Apr 7;13(7):1316-24. doi: 10.1039/c2lc40364a.

14.

Relative Prognostic Value of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Operable Oesophagogastric Cancer.

Chan DS, Campbell F, Edwards P, Jasani B, Williams GT, Lewis WG.

ISRN Surg. 2012;2012:804891. doi: 10.5402/2012/804891. Epub 2012 Jul 26.

15.

Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy.

Larsen MS, Bjerre K, Lykkesfeldt AE, Giobbie-Hurder A, Laenkholm AV, Henriksen KL, Ejlertsen B, Rasmussen BB.

Breast. 2012 Oct;21(5):662-8. doi: 10.1016/j.breast.2012.07.005. Epub 2012 Jul 31.

16.

Statistical association of basal cell keratins with metastasis-inducing proteins in a prognostically unfavorable group of sporadic breast cancers.

de Silva Rudland S, Platt-Higgins A, Winstanley JH, Jones NJ, Barraclough R, West C, Carroll J, Rudland PS.

Am J Pathol. 2011 Aug;179(2):1061-72. doi: 10.1016/j.ajpath.2011.04.022. Epub 2011 Jun 14.

17.

Detection of HER2 amplification in circulating free DNA in patients with breast cancer.

Page K, Hava N, Ward B, Brown J, Guttery DS, Ruangpratheep C, Blighe K, Sharma A, Walker RA, Coombes RC, Shaw JA.

Br J Cancer. 2011 Apr 12;104(8):1342-8. doi: 10.1038/bjc.2011.89. Epub 2011 Mar 22.

18.

HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH).

Boers JE, Meeuwissen H, Methorst N.

Histopathology. 2011 Feb;58(3):383-94. doi: 10.1111/j.1365-2559.2011.03760.x. Epub 2011 Feb 16.

19.

Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study.

Purdie CA, Baker L, Ashfield A, Chatterjee S, Jordan LB, Quinlan P, Adamson DJ, Dewar JA, Thompson AM.

Br J Cancer. 2010 Aug 10;103(4):475-81. doi: 10.1038/sj.bjc.6605799. Epub 2010 Jul 27.

20.

Image analysis as an adjunct to manual HER-2 immunohistochemical review: a diagnostic tool to standardize interpretation.

Dobson L, Conway C, Hanley A, Johnson A, Costello S, O'Grady A, Connolly Y, Magee H, O'Shea D, Jeffers M, Kay E.

Histopathology. 2010 Jul;57(1):27-38. doi: 10.1111/j.1365-2559.2010.03577.x. Epub 2010 Jun 24.

Supplemental Content

Support Center